XenoPort’s Second Pain Failure Puts Heat On Restless Legs
This article was originally published in The Pink Sheet Daily
Executive Summary
With generic Requips making headway in restless legs, investors had counted on cashing in on diabetic neuropathy.
You may also be interested in...
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
An FDA "complete response" letter for the modified gabapentin formula surprised Wall Street, raising questions about similar drugs in development.
Prospects For GSK/XenoPort's Horizant Sink After Rejection By FDA
The news that FDA rejected GlaxoSmithKline/XenoPort's NDA for Horizant (gabapentin enacarbil) for restless leg syndrome due to a carcinogenicity signal in rats took Wall Street by surprise and crushed XenoPort, which lost more than half its market value Feb. 18. The companies issued a press release announcing receipt of an FDA "complete response" letter for Horizant after the market closed on Feb. 17